<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">Further effects of oncolytic influenza A viruses on the cancer-immune microenvironment shown in murine models include activation of NK-cells and macrophage polarization towards immuno-stimulatory M1 phenotypes
 <sup>
  <xref ref-type="bibr" rid="CR66">66</xref>,
  <xref ref-type="bibr" rid="CR114">114</xref>
 </sup>. Recent evidence suggests NS1 deleted influenza virus to exhibit enhanced growth when combined with an IFN blocking agent in vitro
 <sup>
  <xref ref-type="bibr" rid="CR115">115</xref>
 </sup>. Therefore, co-injection with such an agent may lead to intensified initial growth and enhanced subsequent reactions against the tumor. Oncolytic viruses have been combined with multiple agents in preclinical studies, like histone deacetylase inhibitors or the HER2 antibody trastuzumab
 <sup>
  <xref ref-type="bibr" rid="CR116">116</xref>,
  <xref ref-type="bibr" rid="CR117">117</xref>
 </sup>. Such novel combinations may prove to activate immunological anti-cancer mechanisms like antibody-dependent, cell-mediated cytotoxicity (ADCC), which is reduced in breast cancer patients
 <sup>
  <xref ref-type="bibr" rid="CR118">118</xref>,
  <xref ref-type="bibr" rid="CR119">119</xref>
 </sup>. The clinically approved oncolytic virus T-VEC is experimentally combined with other therapeutic modalities, such as radiotherapy
 <sup>
  <xref ref-type="bibr" rid="CR120">120</xref>
 </sup> or immune checkpoint blockade
 <sup>
  <xref ref-type="bibr" rid="CR26">26</xref>,
  <xref ref-type="bibr" rid="CR121">121</xref>
 </sup>. Similar methods may prove to be successful in influenza virus-based oncolytic virotherapy.
</p>
